BRIM Biotech facilitated the enrollment for a Phase III clinical trial of their dry eye disease drug

2023-12-31 / GlobalBio & Investment
Diveinto BRIMBiotechnology,Inc. 'stranslationalmedicinestrategythatfacilitatedtheenrollmentforaPhaseIIIclinicaltrialoftheirdryeyediseasedrugwithinONEyear!✨Discovermorein-depthcoveragehere:https://...

Merck Group is celebrating its 35th anniversary in Taiwan

2024-03-31 / GlobalBio & Investment
#MerckTaiwan35MerckGroupiscelebratingits35thanniversaryinTaiwan.Thecompanyhighlightsitsachievementsandprospectsinitsthreebusinesses:MerckElectronics,MerckHealthcare,andMerckLifeScience.Withafocusoninn...

Explore the realms of biomedical and life sciences in our 111th issue

2023-12-31 / GlobalBio & Investment
Exploretherealmsof #biomedical andlifesciences?Inour111thissue, #Globalbio'sreportersdivedintothedynamic LifeSciencesBaltics in #Lithuania,wherethenationhasputitswholeweightbehindfosteringthegrowt...

08/29《生技股動態》

2024-08-29 / 新聞中心
市場觀測:✔醫影(6637)獲得中榮核醫設備採購案業務,決標金額7.4億元✔精準健康(6991)現增600萬股案,每股10元,基準日9/1108/29一日漲跌(漲)泰福-KY9.99%、瑞基9.94%、易威5.24%(跌)威健生技3.41%、永昕3.09%、台微醫2.95%https://reurl.cc/34eox808/29三大法人動態(買超)美時326張、易威247張、瑞基184張;(賣超)...

Dr. Hsing-Pang Hsieh, Director of IBPR at NHRI is elected to the National Academy of Inventors

2023-12-31 / GlobalBio & Investment
Goldalwaysglitters!CongratulationstoDr. Hsing-PangHsieh,Directorof #IBPR at #NHRI,onbeingelectedtotheNationalAcademyofInventors(#NAI).✨Theirrecognitionofesteemed #innovators likeDr.Hsiehistrulyanhonor...

亞美登創投揭國際醫材趨勢熱點:微創醫材、AI、「5高成長領域」

2024-10-30 / 記者 吳培安
今(30)日,來自美國矽谷、專注於高階醫材的亞美登健康科技創投(AmedVentures),舉辦年度會議「臺美醫療創新:跨域合作與國際市場拓展論壇」,會中介紹全球醫療器材產業發展趨勢,亦邀請到前亞培(Abbott)全球行銷資深副總裁、OstialCorp.執行長MichaelBuck,以及Base5Genomics執行長SolomonEndlich,分別以心血管醫材創新及免疫基因體為題演講。 現...

Eurofins Discovery Taiwan hosted a forum to discuss innovative drug discovery techniques...

2024-03-31 / GlobalBio & Investment
#InnovativeDrugDiscoveryEurofinsDiscoveryTaiwanrecentlyhostedaforumtodiscussinnovativedrugdiscoverytechniquestopotentiallyreduceanimalexperimentation.Theeventfocusedonacceleratingdrugexplorationthroug...

國科會智慧醫療產學聯盟 高雄長庚、彰濱秀傳引領智慧醫療

2024-10-28 / 記者 黃佳啟
今(28)日,國科會展現「智慧醫療產學聯盟」成果,透過學醫產跨域合作,以病患旅程為核心提出創新解決方案,加速智慧醫療產品實證與服務品質提升。高雄長庚紀念醫院展示全球首創的「HOPES平台」,運用AI整合肝癌患者病歷、影像及多體學數據,優化精準治療策略,輔助醫師決策。彰濱秀傳紀念醫院則聚焦智慧微創醫療,結合AI輔助泌尿科病患手術影像診斷,顯著提升手術安全與效率。 國科會產學及園區業務處處長許增如致詞...

The BIO Asia–Taiwan 2024 conference is back on July 24th to 28th

2024-04-30 / GlobalBio & Investment
#BIOAsiaTaiwan2024TheBIOAsia–Taiwan2024conference,organizedbyBIOandTaiwanBioIndustryOrganization(#TaiwanBIO),isback!Savethedate:July24thto28thattheTaipeiNangangExhibitionCenter,#TaiNEX1and2.Here...

PwC released a report titled "2024 Outlook: Global M&A Trends in Health Industries"

2024-04-30 / GlobalBio & Investment
#BioInsights資誠(PwCTaiwan)'sHealthIndustriesPracticehasrecentlyreleasedareporttitled2024Outlook:GlobalM&ATrendsinHealthIndustries.ThereportprojectsanincreaseinM&Aactivitiesin#pharmaceutical...

10/30《生醫焦點雷達》

2024-10-30 / 新聞中心
乳癌患者優先醫療性凍卵補助明年元旦上路聯合報2024/10/30迎戰AI革命浪潮韓國衝刺PIM晶片、量子技術中央社2024/10/28減肥是為了國家經濟!英國研究減肥藥改善慢性病影響生產力效果科技新報2024/10/28能率亞洲攜手輔大搶攻AI智慧醫療商機經濟日報2024/10/29邦睿生技12月登創新板;專注男性不孕醫材MoneyDJ2024/10/29水星生醫*取得科技事業核准函啟動IPO計畫...

保瑞2725萬美元收購美罕藥公司Pyros 估Q4完成  

2024-10-28 / 記者 吳培安
保瑞併購再下一城!今(28)日,保瑞藥業(6472)宣布董事會通過收購位於美國紐澤西州之罕見疾病藥品開發公司PyrosPharmaceuticalsInc.全數股權,進而取得Pyros旗下之關鍵罕見疾病品牌用藥,交割價金為美金2千7百25萬元,預計將於今年第四季交割完成。 保瑞藥業表示,透過此次股權收購所取得的罕病品牌用藥產品組合,將擴大保瑞集團全球銷售業務在美國市場的產品渠道,降低原本過於集中學...